← Eichor
Condition: Moderately To Severely Active Crohn Disease Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Moderately To Severely Active Crohn Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's
Phase 4 · 20 location(s) · University of Calgary · NCT05928039A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Phase 3 · 85 location(s) · Janssen Research & Development, LLC · NCT05923073A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Phase 2/Phase 3 · 367 location(s) · Janssen Research & Development, LLC · NCT07196722Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Col
Phase 1 · 30 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT06754891A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderate
Phase 3 · 187 location(s) · Hoffmann-La Roche · NCT06819891A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in
Phase 3 · 7 location(s) · Hoffmann-La Roche · NCT07298421An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With
Phase N/A · 104 location(s) · AbbVie · NCT06023030A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
Phase 4 · 101 location(s) · Takeda · NCT06581328A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Phase 3 · 138 location(s) · Takeda · NCT06227910A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Phase 2 · 225 location(s) · Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli · NCT06226883An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ
Phase 3 · 301 location(s) · Sanofi · NCT07184931A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
Phase 3 · 41 location(s) · Takeda · NCT05837897A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Di
Phase 3 · 499 location(s) · Merck Sharp & Dohme LLC · NCT06430801A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Phase 3 · 102 location(s) · Janssen Research & Development, LLC · NCT07499232Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Phase 2 · 149 location(s) · Abivax S.A. · NCT06456593A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to
Phase 2 · 190 location(s) · Takeda · NCT06233461VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
Phase 4 · 69 location(s) · Alimentiv Inc. · NCT06257706A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Phase 3 · 22 location(s) · Janssen Research & Development, LLC · NCT07577843Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severel
Phase 3 · 85 location(s) · AbbVie · NCT06332534Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects Wi
Phase 2 · 20 location(s) · Biocad · NCT07078994A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Th
Phase 3 · 85 location(s) · AbbVie · NCT05995353A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Phase 3 · 54 location(s) · Takeda · NCT06100289A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Phase 3 · 96 location(s) · Takeda · NCT04779320A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan
Phase 3 · 372 location(s) · Hoffmann-La Roche · NCT06819878Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Ob
Phase 3 · 186 location(s) · Eli Lilly and Company · NCT06937099A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Phase 2 · 16 location(s) · Takeda · NCT06764615A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti
Phase 3 · 35 location(s) · Sanofi · NCT07184944A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Phase 2 · 71 location(s) · Eli Lilly and Company · NCT07483073A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Phase 2 · 71 location(s) · Eli Lilly and Company · NCT07483099
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.